发酵乳酸aseibacillus Paracasei培养通过调节微生物群衍生的甲酸代谢和巨细胞极化来改善结肠炎
Heng Zhang1, Jingzhou Sun1, Xin Zheng1
1State Key Laboratory of Agricultural Microbiology and College of Life Science and Technology, Huazhong Agricultural University, Wuhan, China.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
|January 15, 2026
概括
高密度发酵的Lacticaseibacillus paracasei (PYW) 通过恢复肠道微生物群和激活免疫通路,有效治疗炎症性肠病 (IBD). 活细菌负载对于PYWW至关重要.
科学领域:
- 微生物学 微生物学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 炎症性肠病 (IBD) 涉及肠道微生物群的免疫失调.
- 益生菌产品为IBD提供了潜在的治疗策略.
- 高密度发酵益生菌对IBD的疗效需要进一步研究.
研究的目的:
- 评估高密度固态发酵乳酸乳酸 (PYW) 对硫酸 (DSS) 诱导的大肠炎的治疗效果.
- 为了比较活体PYW与其无活化后生物 (SPYW) 的疗效.
- 阐明PYW抗结肠病作用背后的机制.
主要方法:
- 在使用DSS的小鼠模型中诱导大肠炎.
- 使用活PYW和非活化的SPYW.
- 分析肠道微生物群结构,托代谢和免疫媒介表达.
- 研究基碳化合物受体 (AhR) 信号通路.
- 通过抗生素耗尽和便微生物群移植 (FMT) 评估微生物群的作用.
主要成果:
- 与SPYW相比,PYW在缓解DSS诱导的大肠炎方面表现出更高的疗效.
- 活性的细菌负载≥5 × 10^10 CFU g^-1对于PYW的治疗效果至关重要.
- PYW恢复了肠道微生物群结构,并丰富了英多尔-3-乳酸 (ILA) 和英多尔-3-酸 (IAA).
- 这些代谢物激活了AhR通路,抑制了促炎媒介,并加强了粘膜壁垒.
- 抗生素的耗尽取消了PYW的好处,而FMT和ILA/IAA补充剂复制了它们.
结论:
- PYW通过一种依赖于微生物群的机制缓解结肠炎,涉及ILA/IAA丰富和AhR通路激活.
- 活细菌的存在对于PYW的治疗疗效是不可或缺的.
- 通过向微生物群-代谢-免疫轴,PYW具有作为IBD益生菌治疗的潜力.
相关概念视频
Drugs for Treatment of Constipation-Predominant IBS
724
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
724
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
643
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
643
Drugs for Treatment of Ulcerative Colitis in IBD
460
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
460
Irritable Bowel Syndrome I: Introduction
923
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
923
Drugs for Treatment of Diarrhea-Predominant IBS
634
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
634
Inflammatory Bowel Disease IV: Pharmacological Management
521
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
521


